Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Review

The complexity of NF-κB signaling in inflammation and cancer

Authors: Bastian Hoesel, Johannes A Schmid

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

The NF-κB family of transcription factors has an essential role in inflammation and innate immunity. Furthermore, NF-κB is increasingly recognized as a crucial player in many steps of cancer initiation and progression. During these latter processes NF-κB cooperates with multiple other signaling molecules and pathways. Prominent nodes of crosstalk are mediated by other transcription factors such as STAT3 and p53 or the ETS related gene ERG. These transcription factors either directly interact with NF-κB subunits or affect NF-κB target genes. Crosstalk can also occur through different kinases, such as GSK3-β, p38, or PI3K, which modulate NF-κB transcriptional activity or affect upstream signaling pathways. Other classes of molecules that act as nodes of crosstalk are reactive oxygen species and miRNAs. In this review, we provide an overview of the most relevant modes of crosstalk and cooperativity between NF-κB and other signaling molecules during inflammation and cancer.
Appendix
Available only for authorised users
Literature
1.
Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986, 46: 705-716. 10.1016/0092-8674(86)90346-6PubMedCrossRef
2.
May MJ, Ghosh S: Signal transduction through NF-kappa B. Immunol Today. 1998, 19: 80-88. 10.1016/S0167-5699(97)01197-3PubMedCrossRef
3.
Caamaño J, Hunter CA: NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev. 2002, 15: 414-429. 10.1128/CMR.15.3.414-429.2002PubMedCentralPubMedCrossRef
4.
May MJ, Ghosh S: Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol. 1997, 8: 63-73. 10.1006/scbi.1997.0057PubMedCrossRef
5.
Marienfeld R: RelB forms transcriptionally inactive complexes with RelA/p65. J Biol Chem. 2003, 278: 19852-19860. 10.1074/jbc.M301945200PubMedCrossRef
6.
Hayden MSM, Ghosh SS: NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26: 203-234. 10.1101/gad.183434.111PubMedCentralPubMedCrossRef
7.
Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U: The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell. 1993, 72: 729-739. 10.1016/0092-8674(93)90401-BPubMedCrossRef
8.
Franzoso G, Bours V, Azarenko V, Park S, Tomita-Yamaguchi M, Kanno T, Brown K, Siebenlist U: The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J. 1993, 12: 3893-3901.PubMedCentralPubMed
9.
Nolan GP, Fujita T, Bhatia K, Huppi C, Liou HC, Scott ML, Baltimore D: The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol. 1993, 13: 3557-3566.PubMedCentralPubMedCrossRef
10.
Wong D, Teixeira A, Oikonomopoulos S, Humburg P, Lone IN, Saliba D, Siggers T, Bulyk M, Angelov D, Dimitrov S, Udalova IA, Ragoussis J: Extensive characterization of NF-κB binding uncovers non-canonical motifs and advances the interpretation of genetic functional traits. Genome Biol. 2011, 12: R70- 10.1186/gb-2011-12-7-r70PubMedCentralPubMedCrossRef
11.
Oeckinghaus A, Ghosh S: The NF- B family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009, 1: a000034-a000034. 10.1101/cshperspect.a000034PubMedCentralPubMedCrossRef
12.
Birbach A, Gold P, Binder BR, Hofer E, De Martin R, Schmid JA: Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J Biol Chem. 2002, 277: 10842-10851. 10.1074/jbc.M112475200PubMedCrossRef
13.
Huang TT, Kudo N, Yoshida M, Miyamoto S: A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci USA. 2000, 97: 1014-1019. 10.1073/pnas.97.3.1014PubMedCentralPubMedCrossRef
14.
Hayden MS, Ghosh S: Shared principles in NF-kappaB signaling. Cell. 2008, 132: 344-362. 10.1016/j.cell.2008.01.020PubMedCrossRef
15.
Tan P, Fuchs SY, Chen A, Wu K, Gomez C, Ronai Z, Pan ZQ: Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of I kappa B alpha. Mol Cell. 1999, 3: 527-533. 10.1016/S1097-2765(00)80481-5PubMedCrossRef
16.
Wu K, Fuchs SY, Chen A, Tan P, Gomez C, Ronai Z, Pan ZQ: The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol Cell Biol. 2000, 20: 1382-1393. 10.1128/MCB.20.4.1382-1393.2000PubMedCentralPubMedCrossRef
17.
Delhase M, Hayakawa M, Chen Y, Karin M: Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science. 1999, 284: 309-313. 10.1126/science.284.5412.309PubMedCrossRef
18.
Schmid JA, Birbach A: IkappaB kinase beta (IKKbeta/IKK2/IKBKB)–a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev. 2008, 19: 157-165. 10.1016/j.cytogfr.2008.01.006PubMedCrossRef
19.
Ling L, Cao Z, Goeddel DV: NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci USA. 1998, 95: 3792-3797. 10.1073/pnas.95.7.3792PubMedCentralPubMedCrossRef
20.
Malinin NL, Boldin MP, Kovalenko AV, Wallach D: MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature. 1997, 385: 540-544. 10.1038/385540a0PubMedCrossRef
21.
Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, Okumura K: Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA. 1998, 95: 3537-3542. 10.1073/pnas.95.7.3537PubMedCentralPubMedCrossRef
22.
Zhao Q: Mitogen-activated protein Kinase/ERK Kinase Kinases 2 and 3 activate nuclear factor-kappa B through Ikappa B Kinase-alpha and Ikappa B Kinase-beta. J Biol Chem. 1999, 274: 8355-8358. 10.1074/jbc.274.13.8355PubMedCrossRef
23.
Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K: The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature. 1999, 398: 252-256. 10.1038/18465PubMedCrossRef
24.
Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ: TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001, 412: 346-351. 10.1038/35085597PubMedCrossRef
25.
Huang Q, Yang J, Lin Y, Walker C, Cheng J, Liu Z-G, Su B: Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol. 2003, 5: 98-103.PubMedCrossRef
26.
Qin J: TLR8-mediated NF- B and JNK Activation Are TAK1-independent and MEKK3-dependent. J Biol Chem. 2006, 281: 21013-21021. 10.1074/jbc.M512908200PubMedCrossRef
27.
Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ: Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 2000, 103: 351-361. 10.1016/S0092-8674(00)00126-4PubMedCrossRef
28.
Habelhah H, Takahashi S, Cho S-G, Kadoya T, Watanabe T, Ronai Z: Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J. 2004, 23: 322-332. 10.1038/sj.emboj.7600044PubMedCentralPubMedCrossRef
29.
30.
Tokunaga F, Sakata S-I, Saeki Y, Satomi Y, Kirisako T, Kamei K, Nakagawa T, Kato M, Murata S, Yamaoka S, Yamamoto M, Akira S, Takao T, Tanaka K, Iwai K: Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat Cell Biol. 2009, 11: 123-132. 10.1038/ncb1821PubMedCrossRef
31.
Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004, 430: 694-699. 10.1038/nature02794PubMedCrossRef
32.
Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G: CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature. 2003, 424: 793-796. 10.1038/nature01803PubMedCrossRef
33.
Perkins ND, Gilmore TD: Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006, 13: 759-772. 10.1038/sj.cdd.4401838PubMedCrossRef
34.
Perkins ND: Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007, 8: 49-62. 10.1038/nrm2083PubMedCrossRef
35.
36.
Xiao G, Harhaj EW, Sun SC: NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell. 2001, 7: 401-409. 10.1016/S1097-2765(01)00187-3PubMedCrossRef
37.
Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li Z-W, Karin M, Ware CF, Green DR: The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity. 2002, 17: 525-535. 10.1016/S1074-7613(02)00423-5PubMedCrossRef
38.
Solan NJ, Miyoshi H, Carmona EM, Bren GD, Paya CV: RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem. 2002, 277: 1405-1418. 10.1074/jbc.M109619200PubMedCrossRef
39.
Senftleben U, Cao Y, Xiao G, Greten FR, Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M: Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. 2001, 293: 1495-1499. 10.1126/science.1062677PubMedCrossRef
40.
Huang TT, Wuerzberger-Davis SM, Wu Z-H, Miyamoto S: Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell. 2003, 115: 565-576. 10.1016/S0092-8674(03)00895-XPubMedCrossRef
41.
Kato T, Delhase M, Hoffmann A, Karin M: CK2 Is a C-terminal IkappaB Kinase responsible for NF-kappaB activation during the UV response. Mol Cell. 2003, 12: 829-839. 10.1016/S1097-2765(03)00358-7PubMedCrossRef
42.
Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, Aggarwal BB: Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem. 2003, 278: 24233-24241. 10.1074/jbc.M212389200PubMedCrossRef
43.
Habib AA: The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem. 2000, 276: 8865-8874.PubMedCrossRef
44.
Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, Sensi M, Canevari S, Tomassetti A: Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene. 2011, 31: 4139-4149.PubMedCrossRef
45.
Tieri P, Termanini A, Bellavista E, Salvioli S, Capri M, Franceschi C: Charting the NF-κB pathway interactome map. PLoS ONE. 2012, 7: e32678- 10.1371/journal.pone.0032678PubMedCentralPubMedCrossRef
46.
Latimer M, Ernst MK, Dunn LL, Drutskaya M, Rice NR: The N-terminal domain of IkappaB alpha masks the nuclear localization signal(s) of p50 and c-Rel homodimers. Mol Cell Biol. 1998, 18: 2640-2649.PubMedCentralPubMedCrossRef
47.
Bouwmeester T, Bauch A, Ruffner H, Angrand P-O, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon A-M, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, Gavin A-C, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, Superti-Furga G: A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat Cell Biol. 2004, 6: 97-105. 10.1038/ncb1086PubMedCrossRef
48.
Scheinman RI, Beg AA, Baldwin AS: NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule. Mol Cell Biol. 1993, 13: 6089-6101.PubMedCentralPubMedCrossRef
49.
Barré B, Perkins ND: A cell cycle regulatory network controlling NF-κB subunit activity and function. EMBO J. 2007, 26: 4841-4855. 10.1038/sj.emboj.7601899PubMedCentralPubMedCrossRef
50.
Ashburner BP, Westerheide SD, Baldwin AS: The p65 (RelA) subunit of NF- B interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol. 2001, 21: 7065-7077. 10.1128/MCB.21.20.7065-7077.2001PubMedCentralPubMedCrossRef
51.
Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T: CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA. 1997, 94: 2927-2932. 10.1073/pnas.94.7.2927PubMedCentralPubMedCrossRef
52.
Chapman NR, Webster GA, Gillespie PJ, Wilson BJ, Crouch DH, Perkins ND: A novel form of the RelA nuclear factor kappaB subunit is induced by and forms a complex with the proto-oncogene c-Myc. Biochem J. 2002, 366: 459-469. 10.1042/BJ20020444PubMedCentralPubMedCrossRef
53.
Frank AK, Leu JI-J, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, Hollstein M, Murphy ME: The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol. 2011, 31: 1201-1213. 10.1128/MCB.01136-10PubMedCentralPubMedCrossRef
54.
Anrather J, Racchumi G, Iadecola C: cis-acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B. Journal of Biological Chemistry. 2004, 280: 244-252.PubMedCrossRef
55.
Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G: Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 2003, 22: 1313-1324. 10.1093/emboj/cdg139PubMedCentralPubMedCrossRef
56.
Nihira K, Ando Y, Yamaguchi T, Kagami Y, Miki Y, Yoshida K: Pim-1 controls NF. Cell Death and Differentiation. 2009, 17: 689-698.PubMedCrossRef
57.
Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S: The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell. 1997, 89: 413-424. 10.1016/S0092-8674(00)80222-6PubMedCrossRef
58.
Jamaluddin M, Wang S, Boldogh I, Tian B, Brasier AR: TNF-α-induced NF-κB/RelA Ser276 phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal. 2007, 19: 1419-1433. 10.1016/j.cellsig.2007.01.020PubMedCrossRef
59.
Duran A, Diaz-Meco MT, Moscat J: Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J. 2003, 22: 3910-3918. 10.1093/emboj/cdg370PubMedCentralPubMedCrossRef
60.
Schwabe RF, Brenner DA: Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2002, 283: G204-G211.PubMedCrossRef
61.
Yang F, Tang E, Guan K, Wang C-Y: IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol. 2003, 170: 5630-5635.PubMedCrossRef
62.
Schwabe RF: IKK phosphorylates p65 at S468 in transactivaton domain 2. 2005, The: FASEB Journal,
63.
Buss H: Constitutive and interleukin-1-inducible phosphorylation of p65 NF- B at serine 536 is mediated by multiple protein kinases including I B kinase (IKK)-, IKK, IKK, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. Journal of Biological Chemistry. 2004, 279: 55633-55643. 10.1074/jbc.M409825200PubMedCrossRef
64.
Mattioli I, Geng H, Sebald A, Hodel M, Bucher C, Kracht M, Schmitz ML: Inducible Phosphorylation of NF- B p65 at Serine 468 by T Cell Costimulation Is Mediated by IKK. Journal of Biological Chemistry. 2006, 281: 6175-6183. 10.1074/jbc.M508045200PubMedCrossRef
65.
Wang D: Tumor necrosis factor alpha -induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. Journal of Biological Chemistry. 2000, 275: 32592-32597.PubMedCrossRef
66.
Soon Bae J, Kyoo Jang M, Hong S, An WG, Choi YH, Kim HD, Cheong J: Phosphorylation of NF-κB by calmodulin-dependent kinase IV activates anti-apoptotic gene expression. Biochem Biophys Res Commun. 2003, 305: 1094-1098. 10.1016/S0006-291X(03)00869-6CrossRef
67.
Delhase M, Kim SY, Lee H, Naiki-Ito A, Chen Y, Ahn ER, Murata K, Kim SJ, Lautsch N, Kobayashi KS, Shirai T, Karin M, Nakanishi M: PNAS Plus: TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proceedings of the National Academy of Sciences. 2012, 109: E177-E186. 10.1073/pnas.1119296109. 10.1073/pnas.1119296109CrossRef
68.
Lawrence T, Bebien M, Liu GY, Nizet V, Karin M: IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature. 2005, 434: 1138-1143. 10.1038/nature03491PubMedCrossRef
69.
Bohuslav J: p53 Induces NF- B activation by an I B kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. Journal of Biological Chemistry. 2004, 279: 26115-26125. 10.1074/jbc.M313509200PubMedCrossRef
70.
Sabatel H, Di Valentin E, Gloire G, Dequiedt F, Piette J, Habraken Y: Phosphorylation of p65(RelA) on Ser547 by ATM represses NF-κB-dependent transcription of specific genes after genotoxic stress. PLoS ONE. 2012, 7: e38246- 10.1371/journal.pone.0038246PubMedCentralPubMedCrossRef
71.
Ryo A, Suizu F, Yoshida Y, Perrem K, Liou Y-C, Wulf G, Rottapel R, Yamaoka S, Lu KP: Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Molecular Cell. 2003, 12: 1413-1426. 10.1016/S1097-2765(03)00490-8PubMedCrossRef
72.
Yeh PY: Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF- B activation by protein phosphatase 4-mediated NF- B p65 Thr dephosphorylation. Journal of Biological Chemistry. 2004, 279: 26143-26148. 10.1074/jbc.M402362200PubMedCrossRef
73.
Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND: Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. 2005, 24: 1157-1169. 10.1038/sj.emboj.7600608PubMedCentralPubMedCrossRef
74.
Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999, 18: 6853-6866. 10.1038/sj.onc.1203239PubMedCrossRef
75.
Klement JF, Rice NR, Car BD, Abbondanzo SJ, Powers GD, Bhatt PH, Chen CH, Rosen CA, Stewart CL: IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol Cell Biol. 1996, 16: 2341-2349.PubMedCentralPubMedCrossRef
76.
Ben-Neriah Y, Karin M: Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011, 12: 715-723.PubMedCrossRef
77.
78.
Smyth MJ, Dunn GP, Schreiber RD: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006, 90: 1-50.PubMedCrossRef
79.
Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol. 2004, 22: 329-360. 10.1146/annurev.immunol.22.012703.104803PubMedCrossRef
80.
Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999, 19: 5785-5799.PubMedCentralPubMedCrossRef
81.
La Rosa FA, Pierce JW, Sonenshein GE: Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol. 1994, 14: 1039-1044.PubMedCentralPubMedCrossRef
82.
Perkins ND: Achieving transcriptional specificity with NF-kappa B. The international journal of biochemistry & cell biology. 1997, 29: 1433-1448. 10.1016/S1357-2725(97)00088-5CrossRef
83.
Liou G-Y, Storz P: Reactive oxygen species in cancer. Free Radic Res. 2010, 44: 479-496. 10.3109/10715761003667554PubMedCrossRef
84.
Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T: NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Investig. 2004, 114: 569-581.PubMedCentralPubMedCrossRef
85.
Xie T-X, Xia Z, Zhang N, Gong W, Huang S: Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol Rep. 2010, 23: 725-732.PubMedCrossRef
86.
Yoshida A, Yoshida S, Ishibashi T, Kuwano M, Inomata H: Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice. Invest Ophthalmol Vis Sci. 1999, 40: 1624-1629.PubMed
87.
Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454: 436-444. 10.1038/nature07205PubMedCrossRef
88.
Courtois G, Gilmore TD: Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene. 2006, 25: 6831-6843. 10.1038/sj.onc.1209939PubMedCrossRef
89.
Neri A, Chang CC, Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RS, Dalla-Favera R: B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell. 1991, 67: 1075-1087. 10.1016/0092-8674(91)90285-7PubMedCrossRef
90.
Fracchiolla NS, Lombardi L, Salina M, Migliazza A, Baldini L, Berti E, Cro L, Polli E, Maiolo AT, Neri A: Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies. Oncogene. 1993, 8: 2839-2845.PubMed
91.
Rayet B, Gélinas C: Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999, 18: 6938-6947. 10.1038/sj.onc.1203221PubMedCrossRef
92.
Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Offit K, Jhanwar SC, Chaganti RS: Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood. 1998, 92: 234-240.PubMed
93.
Ohno H, Takimoto G, McKeithan TW: The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell. 1990, 60: 991-997. 10.1016/0092-8674(90)90347-HPubMedCrossRef
94.
Barth TF, Döhner H, Werner CA, Stilgenbauer S, Schlotter M, Pawlita M, Lichter P, Möller P, Bentz M: Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. Blood. 1998, 91: 4321-4330.PubMed
95.
DiDonato JA, Mercurio F, Karin M: NF-κB and the link between inflammation and cancer. Immunol Rev. 2012, 246: 379-400. 10.1111/j.1600-065X.2012.01099.xPubMedCrossRef
96.
Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin P-C, Svensson MA, Kitabayashi N, Moss BJ, MacDonald TY, Cao X, Barrette T, Tewari AK, Chee MS, Chinnaiyan AM, Rickman DS, Demichelis F, Gerstein MB, Rubin MA: Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 2011, 21: 56-67. 10.1101/gr.110684.110PubMedCentralPubMedCrossRef
97.
Jiao X, Wood LD, Lindman M, Jones S, Buckhaults P, Polyak K, Sukumar S, Carter H, Kim D, Karchin R, Sjöblom T: Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosomes Cancer. 2012, 51: 480-489. 10.1002/gcc.21935PubMedCentralPubMedCrossRef
98.
Greten FR, Eckmann L, Greten TF, Park JM, Li Z-W, Egan LJ, Kagnoff MF, Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004, 118: 285-296. 10.1016/j.cell.2004.07.013PubMedCrossRef
99.
Karin M: NF- B as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009, 1: a000141-a000141. 10.1101/cshperspect.a000141PubMedCentralPubMedCrossRef
100.
Yang J, Splittgerber R, Yull FE, Kantrow S, Ayers GD, Karin M, Richmond A: Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest. 2010, 120: 2563-2574. 10.1172/JCI42358PubMedCentralPubMedCrossRef
101.
Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M: Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 2010, 17: 89-97. 10.1016/j.ccr.2009.12.008PubMedCentralPubMedCrossRef
102.
Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR: “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008, 205: 1261-1268. 10.1084/jem.20080108PubMedCentralPubMedCrossRef
103.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357: 539-545. 10.1016/S0140-6736(00)04046-0PubMedCrossRef
104.
Chefetz I, Holmberg JC, Alvero AB, Visintin I, Mor G: Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway. Cell Cycle. 2011, 10: 2206-2214. 10.4161/cc.10.13.16348PubMedCentralPubMedCrossRef
105.
Alvero AB, Chen R, Fu H-H, Montagna M, Schwartz PE, Rutherford T, Silasi D-A, Steffensen KD, Waldstrom M, Visintin I, Mor G: Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009, 8: 158-166. 10.4161/cc.8.1.7533PubMedCentralPubMedCrossRef
106.
Böhlig L, Rother K: One function—multiple mechanisms: the manifold activities of p53 as a transcriptional repressor. J Biomed Biotechnol. 2011, 2011: 1-15.CrossRef
107.
Grivennikov SI, Karin M: Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21: 11-19. 10.1016/j.cytogfr.2009.11.005PubMedCentralPubMedCrossRef
108.
Perkins ND: The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 2012, 12: 121-132.PubMed
109.
Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR: Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NF B. Genes Dev. 2007, 21: 1396-1408. 10.1101/gad.1553707PubMedCentralPubMedCrossRef
110.
Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R, Haura EB: Stat3 regulates genes common to both wound healing and cancer. Oncogene. 2005, 24: 3397-3408. 10.1038/sj.onc.1208469PubMedCrossRef
111.
Lee H, Herrmann A, Deng J-H, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H: Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009, 15: 283-293. 10.1016/j.ccr.2009.02.015PubMedCentralPubMedCrossRef
112.
Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, Esterbauer H, Mueller M, Casanova E, Kenner L, Poli V, Eferl R: Stat3 Is a negative regulator of intestinal tumor progression in ApcMin mice. YGAST. 2010, 138 (e5): 1003-1011.
113.
114.
Vaughan CA, Singh S, Windle B, Sankala HM, Graves PR, Andrew Yeudall W, Deb SP, Deb S: p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Arch Biochem Biophys. 2012, 518: 79-88. 10.1016/j.abb.2011.12.006PubMedCentralPubMedCrossRef
115.
Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, Wieczorek M, Wagner T, Reichardt S, Werder Von A, Schmid RM, Weih F, Heinzel T, Saur D, Kramer OH: Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene. 2010, 29: 2795-2806. 10.1038/onc.2010.46PubMedCrossRef
116.
Ichikawa H, Shimizu K, Hayashi Y, Ohki M: An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 1994, 54: 2865-2868.PubMed
117.
Prasad DD, Ouchida M, Lee L, Rao VN, Reddy ES: TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. Oncogene. 1994, 9: 3717-3729.PubMed
118.
Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu X-F, Triche TJ, Denny CT: A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994, 6: 146-151. 10.1038/ng0294-146PubMedCrossRef
119.
Tomlins SA: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005, 310: 644-648. 10.1126/science.1117679PubMedCrossRef
120.
Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G, Ittmann M: Activation of NF- B by TMPRSS2/ERG fusion isoforms through toll-like receptor-4. Cancer Res. 2011, 71: 1325-1333. 10.1158/0008-5472.CAN-10-2210PubMedCentralPubMedCrossRef
121.
Dryden NHN, Sperone AA, Martin-Almedina SS, Hannah RLR, Birdsey GMG, Khan STS, Layhadi JAJ, Mason JCJ, Haskard DOD, Göttgens BB, Randi AMA: The transcription factor Erg controls endothelial cell quiescence by repressing activity of nuclear factor (NF)-κB p65. J Biol Chem. 2012, 287: 12331-12342. 10.1074/jbc.M112.346791PubMedCentralPubMedCrossRef
122.
Juan Cai PKRSAKSSMLCSRC: Androgens induce functional CXCR4 through ERG factor expression in TMPRSS2-ERG fusion-positive prostate cancer cells. Translational Oncology. 2010, 3: 195-PubMedCentralPubMedCrossRef
123.
Rylatt DB, Aitken A, Bilham T, Condon GD, Embi N, Cohen P: Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. Eur J Biochem. 1980, 107: 529-537.PubMedCrossRef
124.
125.
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000, 406: 86-90. 10.1038/35017574PubMedCrossRef
126.
Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD: Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005, 65: 2076-2081. 10.1158/0008-5472.CAN-04-3642PubMedCrossRef
127.
Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J, Fine HA: Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 2008, 68: 6643-6651. 10.1158/0008-5472.CAN-08-0850PubMedCentralPubMedCrossRef
128.
Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM: Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene. 2004, 23: 7882-7892. 10.1038/sj.onc.1208068PubMedCrossRef
129.
Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T: Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 2005, 334: 1365-1373. 10.1016/j.bbrc.2005.07.041PubMedCrossRef
130.
Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD: Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood. 2007, 110: 735-742. 10.1182/blood-2006-12-060947PubMedCentralPubMedCrossRef
131.
Schulze-Osthoff K, Ferrari D, Riehemann K, Wesselborg S: Regulation of NF-κB activation by MAP kinase cascades. Immunobiology. 1997, 198: 35-49. 10.1016/S0171-2985(97)80025-3PubMedCrossRef
132.
De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R, Franzoso G: Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature. 2001, 414: 308-313. 10.1038/35104560PubMedCrossRef
133.
Papa S, Zazzeroni F, Bubici C, Jayawardena S, Alvarez K, Matsuda S, Nguyen DU, Pham CG, Nelsbach AH, Melis T, De Smaele E, Tang W-J, D’Adamio L, Franzoso G: Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol. 2004, 6: 146-153. 10.1038/ncb1093PubMedCrossRef
134.
Moscat J, Diaz-Meco MT, Rennert P: NF-kappaB activation by protein kinase C isoforms and B-cell function. EMBO Rep. 2003, 4: 31-36. 10.1038/sj.embor.embor704PubMedCentralPubMedCrossRef
135.
Lin X, O’Mahony A, Mu Y, Geleziunas R, Greene WC: Protein kinase C-theta participates in NF-kappa B activation induced by CD3-CD28 costimulation through selective activation of ikappa B kinase beta. Mol Cell Biol. 2000, 20: 2933-2940. 10.1128/MCB.20.8.2933-2940.2000PubMedCentralPubMedCrossRef
136.
Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP-Y, Baldwin AS: Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes & Development. 2008, 22: 1490-1500. 10.1101/gad.1662308CrossRef
137.
Park YC, Lee CH, Kang HS, Chung HT, Kim HD: Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, enhances LPS-induced NO production from murine peritoneal macrophages. Biochem Biophys Res Commun. 1997, 240: 692-696. 10.1006/bbrc.1997.7722PubMedCrossRef
138.
Guha M: The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. Journal of Biological Chemistry. 2002, 277: 32124-32132. 10.1074/jbc.M203298200PubMedCrossRef
139.
Zhao L, Lee JY, Hwang DH: The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-κB pathway. Biochem Pharmacol. 2008, 75: 1515-1525. 10.1016/j.bcp.2007.12.014PubMedCrossRef
140.
Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, Knaus UG: Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol. 2000, 1: 533-540. 10.1038/82797PubMedCrossRef
141.
Trachootham D, Lu W, Ogasawara MA, Valle NR-D, Huang P: Redox regulation of cell survival. Antioxid Redox Signal. 2008, 10: 1343-1374. 10.1089/ars.2007.1957PubMedCentralPubMedCrossRef
142.
Bhakdi S, Martin E: Superoxide generation by human neutrophils induced by low doses of Escherichia coli hemolysin. Infect Immun. 1991, 59: 2955-2962.PubMedCentralPubMed
143.
144.
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5PubMedCrossRef
145.
Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L, Tamassia N, Mantovani A, Cassatella MA, Locati M: Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci USA. 2009, 106: 5282-5287. 10.1073/pnas.0810909106PubMedCentralPubMedCrossRef
146.
147.
Niu J, Shi Y, Tan G, Yang CH, Fan M, Pfeffer LM, Wu Z-H: DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J Biol Chem. 2012, 287: 21783-21795. 10.1074/jbc.M112.355495PubMedCentralPubMedCrossRef
148.
Zhang X, Liu S, Hu T, Liu S, He Y, Sun S: Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology. 2009, 50: 490-499. 10.1002/hep.23008PubMedCrossRef
149.
Taganov KD, Boldin MP, Chang K-J, Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006, 103: 12481-12486. 10.1073/pnas.0605298103PubMedCentralPubMedCrossRef
150.
Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Laco R, D’Onorio De Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G, Levrero M, Pediconi N: Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol. 2012, 56: 855-861. 10.1016/j.jhep.2011.11.017PubMedCrossRef
151.
Iliopoulos D, Hirsch HA, Struhl K: An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009, 139: 693-706. 10.1016/j.cell.2009.10.014PubMedCentralPubMedCrossRef
152.
Li T, Morgan MJ, Choksi S, Zhang Y, Kim Y-S, Liu Z-G: MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat Immunol. 2010, 11: 799-805. 10.1038/ni.1918PubMedCentralPubMedCrossRef
153.
Zhang S, Shan C, Kong G, Du Y, Ye L, Zhang X: MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK). Oncogene. 2012, 31: 3607-3620. 10.1038/onc.2011.523PubMedCrossRef
154.
Ahn D-W, Seo JK, Lee SH, Hwang J-H, Lee JK, Ryu JK, Kim Y-T, Yoon YB: Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer. Pancreas. 2012, 41: 1048-1057. 10.1097/MPA.0b013e318249d62ePubMedCrossRef
155.
Walsby E, Pearce L, Burnett AK, Fegan C, Pepper C: The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget. 2012, 3: 525-534.PubMedCentralPubMedCrossRef
156.
Buontempo F, Chiarini F, Bressanin D, Tabellini G, Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA, Martelli AM: Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle. 2012, 11: 2467-2475. 10.4161/cc.20859PubMedCrossRef
157.
Salem K, Brown CO, Schibler J, Goel A: Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. Exp Hematol. 2013, 41: 209-218. 10.1016/j.exphem.2012.10.002PubMedCentralPubMedCrossRef
158.
Abaza MSI, Bahman AM, Al-Attiyah RJ, Kollamparambil AM: Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action. Tumour Biol. 2012, 33: 1951-1972. 10.1007/s13277-012-0456-6PubMedCrossRef
159.
Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ: BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signal. 2013, 25: 106-112. 10.1016/j.cellsig.2012.09.008PubMedCrossRef
160.
Jiang X-J, Huang K-K, Yang M, Qiao L, Wang Q, Ye J-Y, Zhou H-S, Yi Z-S, Wu F-Q, Wang Z-X, Zhao Q-X, Meng F-Y: Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways. Cancer Letters. 2012, 326: 135-142. 10.1016/j.canlet.2012.07.030PubMedCrossRef
161.
Prasad S, Yadav VR, Sung B, Reuter S, Kannappan R, Deorukhkar A, Diagaradjane P, Wei C, Baladandayuthapani V, Krishnan S, Guha S, Aggarwal BB: Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. Clin Cancer Res. 2012, 18: 4942-4953. 10.1158/1078-0432.CCR-11-2805PubMedCentralPubMedCrossRef
162.
Fabre C, Mimura N, Bobb K, Kong S-Y, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai Y-T, Richardson PG, Hideshima T, Anderson KC: Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012, 18: 4669-4681. 10.1158/1078-0432.CCR-12-0779PubMedCentralPubMedCrossRef
163.
Kunnumakkara AB, Anand P, Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Letters. 2008, 269: 199-225. 10.1016/j.canlet.2008.03.009PubMedCrossRef
164.
Katsman A, Umezawa K, Bonavida B: Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des. 2009, 15: 792-808. 10.2174/138161209787582156PubMedCrossRef
165.
Fuchs O: Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol. 2010, 3: 98-122.PubMedCrossRef
166.
Oiso S, Ikeda R, Nakamura K, Takeda Y, Akiyama S-I, Kariyazono H: Involvement of NF-κB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells. Oncol Rep. 2012, 28: 27-32.PubMed
167.
McConkey DJ, Zhu K: Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008, 11: 164-179. 10.1016/j.drup.2008.08.002PubMedCrossRef
168.
Kozakai N, Kikuchi E, Hasegawa M, Suzuki E, Ide H, Miyajima A, Horiguchi Y, Nakashima J, Umezawa K, Shigematsu N, Oya M: Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer. Br J Cancer. 2012, 107: 652-657. 10.1038/bjc.2012.321PubMedCentralPubMedCrossRef
Metadata
Title
The complexity of NF-κB signaling in inflammation and cancer
Authors
Bastian Hoesel
Johannes A Schmid
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-86

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells

Research

Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer

Research

Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site

Research

Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer

Research

Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma

Research

Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits